BRMS1L抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09029(BRMS1L Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09029(BRMS1L Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

The BRMS1L (Breast cancer metastasis suppressor 1-like) antibody is a tool used to detect the BRMS1L protein, a member of the metastasis suppressor gene family closely related to BRMS1. Initially identified for its role in inhibiting breast cancer metastasis, BRMS1L is now recognized as a multifunctional regulator in cancer biology and epigenetic regulation. Structurally, BRMS1L contains conserved domains, including an NLRP (NACHT) domain and coiled-coil regions, enabling interactions with chromatin-modifying complexes like the mSin3A-HDAC complex. It participates in transcriptional repression, histone deacetylation, and chromatin remodeling, influencing pathways such as apoptosis, cell migration, and metastasis.

Research highlights BRMS1L's tumor-suppressive roles in various cancers (e.g., breast, lung, liver) by modulating oncogenic signaling, including Hippo and Wnt pathways. Dysregulation of BRMS1L is linked to poor prognosis and therapeutic resistance. The BRMS1L antibody facilitates studies on its expression patterns, subcellular localization, and mechanistic roles in vitro and in vivo. Applications span Western blotting, immunohistochemistry, and co-immunoprecipitation, aiding discoveries in cancer progression, epigenetic dysregulation, and potential therapeutic targets. Its development underscores the growing interest in metastasis suppressor proteins as biomarkers and intervention points in precision oncology.